Monofer (Ferric Derisomaltose)

Ferric derisomaltose, the active ingredient in Monofer, is an iron supplement presented as an injectable solution for intravenous use. It treats iron deficiency anemia in adults and children when oral iron is insufficient or not tolerated.

GNH USA supplies Monofer as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Monofer is an intravenous iron product used to correct iron deficiency across several clinical settings.

Iron deficiency anemia: increases hemoglobin levels and replenishes depleted iron stores. Chronic kidney disease‑associated anemia: provides intravenous iron when oral therapy is ineffective. Pre‑operative anemia: corrects iron deficiency before surgery to reduce the need for blood transfusion.

Monofer may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea - Headache - Dizziness - Injection‑site pain or erythema - Transient hypotension during infusion - Flushing or warmth sensation

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions - Acute respiratory distress syndrome - Severe hypotensive shock - Significant liver enzyme elevations - Severe hypertension or hypertensive crisis - Iron overload with prolonged high‑dose therapy

Monofer should be used with careful clinical assessment and monitoring.

Assess iron status before use: confirm diagnosis of iron deficiency anemia. Monitor hemoglobin and ferritin levels: adjust therapy based on response. Avoid in patients with known hypersensitivity to ferric derisomaltose or its excipients. Use cautiously in active infections: iron may promote bacterial growth. Observe for hypotension during infusion: administer under medical supervision. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Monofer can interact with other agents that affect iron metabolism or cardiovascular stability.

Major Interactions (Avoid): - Concurrent use of other intravenous iron products: risk of iron overload. - Combination with erythropoiesis‑stimulating agents without monitoring: may cause excessive hemoglobin rise. - Use in patients with hereditary hemochromatosis: contraindicated due to iron accumulation risk.

Moderate Interactions (Monitor Closely): - Oral iron supplements taken simultaneously: may reduce absorption of ferric derisomaltose. - Antacids containing aluminum or magnesium: can affect iron release. - Chelating agents such as deferoxamine: may bind released iron and alter efficacy.